PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression
Milton Boaheng Antwi, Sander Lefere, Dorien Clarisse, Lisa L. Koorneef, Anneleen Heldens, Louis Onghena, Kylian Decroix, Daria Fijałkowska, Jonathan Thommis, Madeleine Hellemans, Anne Hoorens, Anja M. Geerts, Lindsey Devisscher, Karolien De Bosscher
This study shows that targeting PPAR and ERR receptors reduces liver fat, fibrosis, and inflammation in MASLD models, suggesting a new therapeutic strategy.
Metabolism · Dec 30, 2024Peer-reviewedPharmacology & Toxicology